Erythema infectiosum (Fifth disease)

Erythema infectiosum (fifth disease) is a viral illness caused by B19 parvovirus, and human parvovirus B19 is identified as the agent responsible for this syndrome ^[1][3]. It is characterized in the literature as a common benign pediatric condition and as the most common of several clinical syndromes associated with parvovirus B19 ^[1][3]. Source-backed details on broader case definitions or formal surveillance classification are not yet available.

The typical presentation is a febrile exanthem in children, with a clinically recognizable "slapped cheek" appearance that is often followed by a reticulated exanthem on the trunk and extremities ^[3][1]. The rash may be prominent, and generalized symptoms are noted in review material, although the snippets do not further specify their full spectrum ^[1]. The condition is usually self-limited in children and is described as having an excellent prognosis ^[1]. Parvovirus B19 has also been associated with acute arthritis and, occasionally, chronic arthropathy in both children and adults ^[3].

Erythema infectiosum is reported as a common childhood exanthem, occurring most often in children ages 4 to 15 years ^[2][1]. Peak incidence is described in winter and spring ^[2]. The disease can occur in focal outbreaks or in community-wide epidemics, and these outbreaks may last 3 to 6 months ^[2]. Infection rates of 20% to 50% have been noted in families and classrooms ^[2].

The provided source snippets identify the etiologic virus but do not give a source-backed transmission route or exposure mechanism for erythema infectiosum ^[1][3]. Source-backed detail on persistence, shedding, or specific contact pathways is not yet available.

The clearest source-supported risk group is children, particularly those aged 4 to 15 years, in whom the condition is most often seen ^[2][1]. The snippets also indicate that parvovirus B19-associated arthritis and chronic arthropathy can occur in adults as well as children, but they do not further specify vulnerability by age, pregnancy, immunocompromise, or other subgroups ^[3].

The snippets do not provide source-backed preventive measures, immunization information, or specific exposure-control recommendations for erythema infectiosum ^[1][2]. For surveillance use, prevention should therefore be described only at the level supported by the available sources.

For monitoring purposes, erythema infectiosum should be interpreted as a frequent pediatric parvovirus B19-associated exanthem that may appear in winter and spring and may produce family, classroom, or community outbreaks ^[2][1]. The literature also notes associated arthritic manifestations, which may broaden the clinical picture in surveillance data ^[3]. Source-backed detail on laboratory confirmation thresholds or reporting criteria is not yet available.

1. 1 Vafaie J et al. Erythema infectiosum. J Cutan Med Surg. 2005 Aug. PMID: 16502203. doi: 10.1007/s10227-005-0101-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/16502203/
2. 2 Erythema Infectiosum (Fifth Disease). Pediatrics In Review. 1995. doi: 10.1542/pir.16.12.474. DOI: https://doi.org/10.1542/pir.16.12.474
3. 3 Moore TL et al. Parvovirus-associated arthritis. Curr Opin Rheumatol. 2000 Jul. PMID: 10910181. doi: 10.1097/00002281-200007000-00010. PubMed: https://pubmed.ncbi.nlm.nih.gov/10910181/
4. 4 Chorba T et al. Erythema infectiosum (fifth disease). Clin Dermatol. 1989 Jan-Mar. PMID: 2538215. doi: 10.1016/0738-081x(89)90030-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/2538215/
5. 5 Erythema infectiosum (fifth disease). Clinics in Dermatology. 1989. doi: 10.1016/0738-081x(89)90030-8. DOI: https://doi.org/10.1016/0738-081x(89)90030-8
6. 6 Erythema Infectiosum (Fifth Disease). Clinical Pediatrics. 1969. doi: 10.1177/000992286900801212. DOI: https://doi.org/10.1177/000992286900801212

ICD-10

ICD-11

Total cases

582K

Peak month

2025-08

Coverage

1 reporting countries · 2012-09-15 → 2026-06-20